Skip to content

Clinical effect evaluation of Guben Qushi Prescription in treating dampness of spleen deficiency eczema

Clinical effect evaluation of Guben Qushi Prescription in treating dampness of spleen deficiency eczema

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006104
Enrollment
Unknown
Registered
2022-06-12
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eczema

Interventions

1:Chinese medicine
2:placebo

Sponsors

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of Western medicine for eczema; (2) Conforms to the diagnostic criteria of spleen deficiency and dampness accumulation syndrome of TRADITIONAL Chinese medicine (determined by combining the industry standards of TRADITIONAL Chinese medicine and the preliminary research results of the research group); (3) Age: 18-65; (4) 7 < eczema area and severity index (EASI) =21; (5) skin area =3% (3% is equivalent to 3 palm area); (6) Voluntarily participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with abnormal blood system, liver, kidney, heart and other systems; (2) patients suffering from mental diseases, malignant tumors, diabetes and heart disease, and pregnant and lactating women; (3) with other skin diseases; (4) Systematic use of glucocorticoids or immunosuppressants (including Tripterygium wilfordii) in the last 4 weeks; (5) known allergic to test drug components.

Design outcomes

Primary

MeasureTime frame
EASI(Eczema area and severity index);

Secondary

MeasureTime frame
VAS(Visual Analog Scale);DLQI(dermatology life quality index);POEM(Patient Oriented Eczema Measure);

Countries

China

Contacts

Public ContactMo Xiumei
moxiumeilsamay@163.com13650755038

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026